{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T17:24:36Z","timestamp":1794590676425,"version":"4.9.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T00:00:00Z","timestamp":1652140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T00:00:00Z","timestamp":1652140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To evaluate the effects of a combined oral contraceptive containing 1.5\u00a0mg 17b-estradiol (E2) and 2.5\u00a0mg nomegestrol acetate (NOMAC) or 2\u00a0mg\/daily dienogest (DNG) oral progestin on endometriosis-associated chronic pelvic pain (CPP) and on the quality of life (QoL) and sexual function, by a randomized study design.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The E2\/NOMAC group and DNG group included 99 and 98 women, respectively. The levels of CPP were measured by the visual analogic scale (VAS). The QoL scores were investigated by the Short Form-36 questionnaire (SF-36). Finally, sexual function was studied using the Female Sexual Function Index (FSFI), while sexual distress was studied by the Female Sexual Distress Scale (FSDS). The study had 3, 6 and 12-month follow-ups.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The intra-group analysis showed an improvement of the VAS score from baseline to the 12-month follow-up in the women of both groups (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). The inter-group comparison showed a similar improvement of CPP (<jats:italic>p<\/jats:italic>\u2009=\u20090.06). Women on DNG had better SF-36 somatic (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01) and FSFI scores (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.006) than women on E2\/NOMAC at the 6- and 12-month follow-ups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The results support the efficacy of both hormonal treatments, even if DNG was more effective than E2\/NOMAC in a limited intergroup comparison.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12905-022-01737-7","type":"journal-article","created":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T12:06:48Z","timestamp":1652184408000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Randomized study on the effectiveness of nomegestrol acetate plus 17\u03b2-estradiol oral contraceptive versus dienogest oral pill in women with suspected endometriosis\u2011associated chronic pelvic pain"],"prefix":"10.1186","volume":"22","author":[{"given":"Salvatore","family":"Caruso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cianci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Iraci Sareri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Panella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Cianci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,10]]},"reference":[{"key":"1737_CR1","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1177\/1933719108330568","volume":"16","author":"PA Rogers","year":"2009","unstructured":"Rogers PA, D\u2019Hooghe TM, Fazleabas A, Gargett CE, Giudice LC, et al. Priorities for endometriosis research: recommendations from an international consensus workshop. Reprod Sci. 2009;16:335\u201346.","journal-title":"Reprod Sci"},{"issue":"7","key":"1737_CR2","volume":"30","author":"J Marjoribanks","year":"2015","unstructured":"Marjoribanks J, Ayeleke RO, Farquhar C, Proctor M. Nonsteroidal anti-inflammatory drugs for dysmenorrhea. Cochrane Database Syst Rev. 2015;30(7): CD001751.","journal-title":"Cochrane Database Syst Rev"},{"key":"1737_CR3","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1097\/GRF.0000000000000299","volume":"60","author":"LA Bishop","year":"2017","unstructured":"Bishop LA. Management of chronic pelvic pain. Clin Obstet Gynecol. 2017;60:524\u201330.","journal-title":"Clin Obstet Gynecol"},{"key":"1737_CR4","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/S0015-0282(03)00794-5","volume":"80","author":"P Vercellini","year":"2003","unstructured":"Vercellini P, Frontino G, De Giorgi O, Pietropaolo G, Pasin R. Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen. Fertil Steril. 2003;80:560\u20133.","journal-title":"Fertil Steril"},{"key":"1737_CR5","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1186\/s12905-021-01545-5","volume":"21","author":"DR Kalaitzopoulos","year":"2021","unstructured":"Kalaitzopoulos DR, Samartzis N, Kolovos GN, Mareti E, Samartzis EP, Eberhard M, Dinas K, Daniilidis A. Treatment of endometriosis: a review with comparison of 8 guidelines. BMC Women\u2019s Health. 2021;21:397. https:\/\/doi.org\/10.1186\/s12905-021-01545-5.","journal-title":"BMC Women\u2019s Health"},{"key":"1737_CR6","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1016\/j.fertnstert.2016.10.022","volume":"106","author":"P Vercellini","year":"2016","unstructured":"Vercellini P, Buggio L, Berlanda N, Barbara G, Somigliana E, Bosari S. Estrogen-progestins and progestins for the management of endometriosis. Fertil Steril. 2016;106:1552-1571.e2.","journal-title":"Fertil Steril"},{"key":"1737_CR7","doi-asserted-by":"publisher","first-page":"10554","DOI":"10.3390\/ijms221910554","volume":"22","author":"B Smolarz","year":"2021","unstructured":"Smolarz B, Szy\u0142\u0142o K, Romanowicz H. Endometriosis: epidemiology, classification, pathogenesis, treatment and genetics (review of literature). Int J Mol Sci. 2021;22:10554. https:\/\/doi.org\/10.3390\/ijms221910554.","journal-title":"Int J Mol Sci"},{"key":"1737_CR8","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2165\/11532130-000000000-00000","volume":"70","author":"S Lello","year":"2010","unstructured":"Lello S. Nomegestrol acetate: pharmacology, safety profile and therapeutic efficacy. Drugs. 2010;70:541\u201359.","journal-title":"Drugs"},{"key":"1737_CR9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2217\/WHE.09.72","volume":"6","author":"T Harada","year":"2010","unstructured":"Harada T, Taniguchi F. Dienogest: a new therapeutic agent for the treatment of endometriosis. Womens Health (Lond Engl). 2010;6:27\u201335.","journal-title":"Womens Health (Lond Engl)"},{"key":"1737_CR10","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1093\/humrep\/det457","volume":"29","author":"GAJ Dunselman","year":"2014","unstructured":"Dunselman GAJ, Vermeulen N, Becker C, et al. European Society of Human Reproduction and Embryology. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014;29:400\u201312.","journal-title":"Hum Reprod"},{"key":"1737_CR11","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1067\/mem.2001.118863","volume":"38","author":"EJ Gallagher","year":"2001","unstructured":"Gallagher EJ, Liebman M, Bijur PE. Prospective validation of clinically important changes in pain severity measured on a visual analog scale. Ann Emerg Med. 2001;38:633\u20138.","journal-title":"Ann Emerg Med"},{"key":"1737_CR12","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S0895-4356(98)00107-3","volume":"51","author":"P Bech","year":"1998","unstructured":"Bech P, Brazier J, Bullinger M, et al. The factor structure of the SF-36 Health Survey in 10 countries: results from the International Quality of Life Assessment (IQOLA) project. J Clin Epidemiol. 1998;51:1159\u201365.","journal-title":"J Clin Epidemiol"},{"key":"1737_CR13","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1080\/09513590801925596","volume":"24","author":"RE Nappi","year":"2008","unstructured":"Nappi RE, Albani F, Vaccaro P, et al. Use of the Italian translation of the Female Sexual Function Index (FSFI) in routine gynecological practice. Gynecol Endocrinol. 2008;24:214\u20139.","journal-title":"Gynecol Endocrinol"},{"key":"1737_CR14","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1080\/00926230290001448","volume":"28","author":"LR Derogatis","year":"2002","unstructured":"Derogatis LR, Rosen R, Leiblum S, Burnett A, Heiman J. The Female Sexual Distress Scale (FSDS): Initial validation of a standardized scale for assessment of sexually related personal in distress women. J Sex Marital Ther. 2002;28:317\u201330.","journal-title":"J Sex Marital Ther"},{"key":"1737_CR15","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1080\/13625187.2018.1433824","volume":"23","author":"S Caruso","year":"2018","unstructured":"Caruso S, Cianci S, Vitale SG, Fava V, Cutello S, Cianci A. Sexual function and quality of life of women adopting the levonorgestrel-releasing intrauterine system (LNG-IUS 13.5 mg) after abortion for unintended pregnancy. Eur J Contracept Reprod Health Care. 2018;23:24\u201332.","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"1737_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s10397-021-01096-5","author":"MN D\u2019Alterio","year":"2021","unstructured":"D\u2019Alterio MN, Saponara S, Agus M, Lagan\u00e0 AS, Noventa M, StochinoLoi E, Feki A, Angioni S. Medical and surgical interventions to improve the quality of life for endometriosis patients: a systematic review. Gynecol Surg. 2021. https:\/\/doi.org\/10.1186\/s10397-021-01096-5.","journal-title":"Gynecol Surg"},{"key":"1737_CR17","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1080\/09513590.2020.1725965","volume":"36","author":"M Vignali","year":"2020","unstructured":"Vignali M, Belloni GM, Pietropaolo G, Barbasetti Di Prun A, Barbera V, Angioni S, Pino I. Effect of dienogest therapy on the size of the endometrioma. Gynecol Endocrinol. 2020;36:723\u20137.","journal-title":"Gynecol Endocrinol"},{"key":"1737_CR18","first-page":"88","volume":"15","author":"MN D'Alterio","year":"2021","unstructured":"D\u2019Alterio MN, D\u2019Ancona G, Raslan M, Tinelli R, Daniilidis A, Angioni S. Management challenges of deep infiltrating endometriosis. Int J Fertil Steril. 2021;15:88\u201394.","journal-title":"Int J Fertil Steril"},{"key":"1737_CR19","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.2147\/JPR.S207599","volume":"12","author":"S Caruso","year":"2019","unstructured":"Caruso S, Iraci M, Cianci S, Vitale SG, Fava V, Cianci A. Effects of long-term treatment with Dienogest on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain. J Pain Res. 2019;12:2371\u20138.","journal-title":"J Pain Res"},{"key":"1737_CR20","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.maturitas.2008.11.013","volume":"61","author":"AE Schindler","year":"2008","unstructured":"Schindler AE, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturitas. 2008;61:171\u201380.","journal-title":"Maturitas"},{"key":"1737_CR21","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1177\/0091270011423664","volume":"52","author":"C Klipping","year":"2012","unstructured":"Klipping C, Duijkers I, Remmers A, et al. Ovulation-inhibiting effects of dienogest in a randomized, dose-controlled pharmacodynamic trial of healthy women. J Clin Pharmacol. 2012;52:1704\u201313.","journal-title":"J Clin Pharmacol"},{"key":"1737_CR22","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1177\/1933719114556488","volume":"22","author":"G Grandi","year":"2015","unstructured":"Grandi G, Xholli A, Napolitano A, Palma F, Cagnacci A. Pelvic pain and quality of life of women with endometriosis during quadriphasic estradiol valerate\/dienogest oral contraceptive: a patient-preference prospective 24-week pilot study. Reprod Sci. 2015;22:626\u201332.","journal-title":"Reprod Sci"},{"key":"1737_CR23","doi-asserted-by":"publisher","first-page":"3822","DOI":"10.3390\/ijms20153822","volume":"20","author":"RM Marquardt","year":"2019","unstructured":"Marquardt RM, Kim TH, Shin JH, Jeong JW. Progesterone and estrogen signaling in the endometrium: what goes wrong in endometriosis? Int J Mol Sci. 2019;20:3822.","journal-title":"Int J Mol Sci"},{"key":"1737_CR24","first-page":"4474","volume":"83","author":"K Zeitoun","year":"1998","unstructured":"Zeitoun K, Takayama K, Sasano H, et al. Deficient 17beta-hydroxysteroid dehydrogenase type 2 expression in endometriosis: failure to metabolize 17beta-estradiol. J Clin Endocrinol Metab. 1998;83:4474\u201380.","journal-title":"J Clin Endocrinol Metab"},{"key":"1737_CR25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejogrb.2016.07.497","volume":"209","author":"M Morotti","year":"2017","unstructured":"Morotti M, Vincent K, Becker CM. Mechanisms of pain in endometriosis. Eur J Obstet Gynecol Reprod Biol. 2017;209:8\u201313.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"1737_CR26","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/00042192-200011000-00003","volume":"7","author":"L Speroff","year":"2000","unstructured":"Speroff L, Symons J, Kempfert N, Rowan J, femhrt Study Investigators. The effect of varying low-dose combinations of norethindrone acetate and ethinyl estradiol (femhrt) on the frequency and intensity of vasomotor symptoms. Menopause. 2000;7:383\u201390.","journal-title":"Menopause"},{"key":"1737_CR27","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1080\/09513590.2018.1433160","volume":"34","author":"G Brichant","year":"2018","unstructured":"Brichant G, Nervo P, Albert A, Munaut C, Foidart JM, Nisolle M. Heterogeneity of estrogen receptor \u03b1 and progesterone receptor distribution in lesions of deep infiltrating endometriosis of untreated women or during exposure to various hormonal treatments. Gynecol Endocrinol. 2018;34:651\u20135.","journal-title":"Gynecol Endocrinol"},{"key":"1737_CR28","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.steroids.2010.08.010","volume":"76","author":"Y Shimizu","year":"2011","unstructured":"Shimizu Y, Mita S, Takeuchi T, Notsu T, Mizuguchi K, Kyo S. Dienogest, a synthetic progestin, inhibits prostaglandin E2 production and aromatase expression by human endometrial epithelial cells in a spheroid culture system. Steroids. 2011;76:60\u20137.","journal-title":"Steroids"},{"key":"1737_CR29","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1530\/JOE-15-0052","volume":"225","author":"T Mori","year":"2015","unstructured":"Mori T, Ito F, Matsushima H, Takaoka O, Koshiba A, Tanaka Y, Kusuki I, Kitawaki J. Dienogest reduces HSD17\u03b21 expression and activity in endometriosis. J Endocrinol. 2015;225:69\u201376.","journal-title":"J Endocrinol"},{"key":"1737_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsbmb.2004.11.004","volume":"93","author":"J Shields-Botella","year":"2005","unstructured":"Shields-Botella J, Chetrite G, Meschi S, Pasqualini JR. Effect of nomegestrol acetate on estrogen biosynthesis and transformation in MCF-7 and T47-D breast cancer cells. J Steroid Biochem Mol Biol. 2005;93:1\u201313.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"1737_CR31","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.contraception.2012.07.001","volume":"87","author":"MG Gerrits","year":"2013","unstructured":"Gerrits MG, Schnabel PG, Post TM, Peeters PA. Pharmacokinetic profile of nomegestrolacetate and 17\u03b2-estradiol after multiple and single dosing in healthy women. Contraception. 2013;87:193\u2013200.","journal-title":"Contraception"},{"key":"1737_CR32","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1210\/er.2018-00242","volume":"40","author":"SE Bulun","year":"2019","unstructured":"Bulun SE, Yilmaz BD, Sison C, et al. Endometriosis. Endocr Rev. 2019;40:1048\u201379.","journal-title":"Endocr Rev"},{"key":"1737_CR33","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2147\/IJWH.S107586","volume":"8","author":"P Briggs","year":"2016","unstructured":"Briggs P, Serrani M, Vogtl\u00e4nder K, Parke S. Continuation rates, bleeding profile acceptability, and satisfaction of women using an oral contraceptive pill containing estradiol valerate and dienogest versus a progestogen-only pill after switching from an ethinylestradiol-containing pill in a real-life setting: results of the CONTENT study. Int J Womens Health. 2016;8:477\u201387.","journal-title":"Int J Womens Health"},{"key":"1737_CR34","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1080\/09513590.2021.1878134","volume":"37","author":"S Clemenza","year":"2021","unstructured":"Clemenza S, Vannuccini S, Capezzuoli T, Meleca CI, Pampaloni F, Petraglia F. Is primary dysmenorrhea a precursor of future endometriosis development? Gynecol Endocrinol. 2021;37:287\u201393.","journal-title":"Gynecol Endocrinol"},{"key":"1737_CR35","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12958-018-0347-9","volume":"16","author":"B Liang","year":"2018","unstructured":"Liang B, Wu L, Xu H, Cheung CW, Fung WY, Wong SW, et al. Efficacy, safety and recurrence of new progestins and selective progesterone receptor modulator for the treatment of endometriosis: a comparison study in mice. Reprod Biol Endocrinol. 2018;16:32.","journal-title":"Reprod Biol Endocrinol"},{"key":"1737_CR36","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.fertnstert.2017.01.003","volume":"107","author":"RF Casper","year":"2017","unstructured":"Casper RF. Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills. Fertil Steril. 2017;107:533\u20136.","journal-title":"Fertil Steril"},{"key":"1737_CR37","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1089\/jwh.2020.8291","volume":"29","author":"S Caruso","year":"2020","unstructured":"Caruso S, Cianci A, Iraci M, Fava V, Di Pasqua S, Cianci S. Does Nomegestrol acetate plus 17\u03b2-estradiol oral contraceptive improve endometriosis-associated chronic pelvic pain in women? J Women\u2019s Health (Larchmt). 2020;29:1184\u201391.","journal-title":"J Women\u2019s Health (Larchmt)"},{"key":"1737_CR38","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1111\/j.1743-6109.2011.02409.x","volume":"8","author":"S Caruso","year":"2011","unstructured":"Caruso S, Agnello C, Romano M, Cianci S, Lo Presti L, Malandrino C, Cianci A. Preliminary study on the effect of four-phasic estradiol valerate and dienogest (E2V\/DNG) oral contraceptive on the quality of sexual life. J Sex Med. 2011;8:2841\u20135.","journal-title":"J Sex Med"},{"key":"1737_CR39","doi-asserted-by":"publisher","DOI":"10.1097\/PR9.0000000000000886","volume":"6","author":"RH Dworkin","year":"2021","unstructured":"Dworkin RH, Kerns RD, McDermott MP, Turk DC, Veasley C. The ACTTION guide to clinical trials of pain treatments, part II: mitigating bias, maximizing value. Pain Rep. 2021;6: e886. https:\/\/doi.org\/10.1097\/PR9.0000000000000886.","journal-title":"Pain Rep"},{"key":"1737_CR40","doi-asserted-by":"publisher","first-page":"54","DOI":"10.23736\/S0026-4784.18.04320-4","volume":"71","author":"L Muzii","year":"2019","unstructured":"Muzii L, Di Tucci C, Di Feliciantonio M, Galati G, Marchetti C, Perniola G, Pecorini F, Benedetti PP. Management of endometriosis from diagnosis to treatment: roadmap for the future. Minerva Ginecol. 2019;71:54\u201361.","journal-title":"Minerva Ginecol"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-022-01737-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-022-01737-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-022-01737-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T12:08:55Z","timestamp":1652184535000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/s12905-022-01737-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,10]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1737"],"URL":"https:\/\/doi.org\/10.1186\/s12905-022-01737-7","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,10]]},"assertion":[{"value":"3 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics Committee Catania 1, University Hospital Polyclinic, Catania, Italy, approved the study protocol. It conformed to the ethical guidelines of the 2013 Helsinki Declaration. Informed consent was obtained from all the study participants\/or their legal guardians.The research protocol was approved by the institutional review board of the Ethics Committee of the University Hospital Polyclinic, Catania, Italy, registered n. 109\/2017\/PO.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"146"}}